203 related articles for article (PubMed ID: 29340623)
1. Pharmacokinetics of rituximab and clinical outcomes in patients with anti-neutrophil cytoplasmic antibody associated vasculitis.
Cornec D; Kabat BF; Mills JR; Cheu M; Hummel AM; Schroeder DR; Cascino MD; Brunetta P; Murray DL; Snyder MR; Fervenza F; Hoffman GS; Kallenberg CGM; Langford CA; Merkel PA; Monach PA; Seo P; Spiera RF; St Clair EW; Stone JH; Barnidge DR; Specks U
Rheumatology (Oxford); 2018 Apr; 57(4):639-650. PubMed ID: 29340623
[TBL] [Abstract][Full Text] [Related]
2. Highly Sensitive Flow Cytometric Detection of Residual B-Cells After Rituximab in Anti-Neutrophil Cytoplasmic Antibodies-Associated Vasculitis Patients.
van Dam LS; Oskam JM; Kamerling SWA; Arends EJ; Bredewold OW; Berkowska MA; van Dongen JJM; Rabelink TJ; van Kooten C; Teng YKO
Front Immunol; 2020; 11():566732. PubMed ID: 33384685
[TBL] [Abstract][Full Text] [Related]
3. The association of serum interleukin-6 levels with clinical outcomes in antineutrophil cytoplasmic antibody-associated vasculitis.
Berti A; Warner R; Johnson K; Cornec D; Schroeder DR; Kabat BF; Langford CA; Kallenberg CGM; Seo P; Spiera RF; St Clair EW; Fervenza FC; Stone JH; Monach PA; Specks U; Merkel PA;
J Autoimmun; 2019 Dec; 105():102302. PubMed ID: 31320177
[TBL] [Abstract][Full Text] [Related]
4. Rituximab for remission induction in elderly patients with ANCA-associated vasculitis.
Timlin H; Lee SM; Manno RL; Seo P; Geetha D
Semin Arthritis Rheum; 2015 Aug; 45(1):67-9. PubMed ID: 25796088
[TBL] [Abstract][Full Text] [Related]
5. Peripheral CD5+ B cells in antineutrophil cytoplasmic antibody-associated vasculitis.
Unizony S; Lim N; Phippard DJ; Carey VJ; Miloslavsky EM; Tchao NK; Iklé D; Asare AL; Merkel PA; Monach PA; Seo P; St Clair EW; Langford CA; Spiera R; Hoffman GS; Kallenberg CG; Specks U; Stone JH
Arthritis Rheumatol; 2015 Feb; 67(2):535-44. PubMed ID: 25332071
[TBL] [Abstract][Full Text] [Related]
6. Rituximab for anti-neutrophil cytoplasmic antibodies-associated vasculitis: experience of a single center and systematic review of non-randomized studies.
Ayan G; Esatoglu SN; Hatemi G; Ugurlu S; Seyahi E; Melikoglu M; Fresko I; Ozdogan H; Yurdakul S; Hamuryudan V
Rheumatol Int; 2018 Apr; 38(4):607-622. PubMed ID: 29322343
[TBL] [Abstract][Full Text] [Related]
7. Association of Serum Calprotectin (S100A8/A9) Level With Disease Relapse in Proteinase 3-Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
Pepper RJ; Draibe JB; Caplin B; Fervenza FC; Hoffman GS; Kallenberg CG; Langford CA; Monach PA; Seo P; Spiera R; William St Clair E; Tchao NK; Stone JH; Specks U; Merkel PA; Salama AD;
Arthritis Rheumatol; 2017 Jan; 69(1):185-193. PubMed ID: 27428710
[TBL] [Abstract][Full Text] [Related]
8. Non-Linear Rituximab Pharmacokinetics and Complex Relationship between Rituximab Concentrations and Anti-Neutrophil Cytoplasmic Antibodies (ANCA) in ANCA-Associated Vasculitis: The RAVE Trial Revisited.
Bensalem A; Mulleman D; Paintaud G; Azzopardi N; Gouilleux-Gruart V; Cornec D; Specks U; Ternant D
Clin Pharmacokinet; 2020 Apr; 59(4):519-530. PubMed ID: 31586310
[TBL] [Abstract][Full Text] [Related]
9. Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type.
Unizony S; Villarreal M; Miloslavsky EM; Lu N; Merkel PA; Spiera R; Seo P; Langford CA; Hoffman GS; Kallenberg CM; St Clair EW; Ikle D; Tchao NK; Ding L; Brunetta P; Choi HK; Monach PA; Fervenza F; Stone JH; Specks U;
Ann Rheum Dis; 2016 Jun; 75(6):1166-9. PubMed ID: 26621483
[TBL] [Abstract][Full Text] [Related]
10. Impact of rituximab trials on the treatment of ANCA-associated vasculitis.
Alberici F; Jayne DR
Nephrol Dial Transplant; 2014 Jun; 29(6):1151-9. PubMed ID: 24126571
[TBL] [Abstract][Full Text] [Related]
11. Long-term follow-up of patients who received repeat-dose rituximab as maintenance therapy for ANCA-associated vasculitis.
Alberici F; Smith RM; Jones RB; Roberts DM; Willcocks LC; Chaudhry A; Smith KG; Jayne DR
Rheumatology (Oxford); 2015 Jul; 54(7):1153-60. PubMed ID: 25477054
[TBL] [Abstract][Full Text] [Related]
12. B-cell-targeted therapy in systemic vasculitis.
Lally L; Spiera R
Curr Opin Rheumatol; 2016 Jan; 28(1):15-20. PubMed ID: 26599379
[TBL] [Abstract][Full Text] [Related]
13. Rituximab prescription patterns and efficacy in the induction treatment of ANCA-Associated Vasculitis in a Belgian multicenter cohort.
Chasseur P; Blockmans D; von Frenckell C; Nicolas JB; Regniers C; Vandergheynst F
Acta Clin Belg; 2020 Jun; 75(3):163-169. PubMed ID: 30767717
[No Abstract] [Full Text] [Related]
14. Low-dose rituximab as induction therapy for ANCA-associated vasculitis.
Takakuwa Y; Hanaoka H; Kiyokawa T; Iida H; Fujimoto H; Yamasaki Y; Yamada H; Kawahata K
Clin Rheumatol; 2019 Apr; 38(4):1217-1223. PubMed ID: 30680533
[TBL] [Abstract][Full Text] [Related]
15. Dose-dependent Pharmacological Response to Rituximab in the Treatment of Antineutrophil Cytoplasmic Antibody-associated Vasculitis.
Springer JM; Funk RS
J Rheumatol; 2021 Nov; 48(11):1718-1724. PubMed ID: 34334366
[TBL] [Abstract][Full Text] [Related]
16. Impact of rituximab on immunoglobulin concentrations and B cell numbers after cyclophosphamide treatment in patients with ANCA-associated vasculitides.
Venhoff N; Effelsberg NM; Salzer U; Warnatz K; Peter HH; Lebrecht D; Schlesier M; Voll RE; Thiel J
PLoS One; 2012; 7(5):e37626. PubMed ID: 22629432
[TBL] [Abstract][Full Text] [Related]
17. Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2).
Charles P; Terrier B; Perrodeau É; Cohen P; Faguer S; Huart A; Hamidou M; Agard C; Bonnotte B; Samson M; Karras A; Jourde-Chiche N; Lifermann F; Gobert P; Hanrotel-Saliou C; Godmer P; Martin-Silva N; Pugnet G; Matignon M; Aumaitre O; Viallard JF; Maurier F; Meaux-Ruault N; Rivière S; Sibilia J; Puéchal X; Ravaud P; Mouthon L; Guillevin L;
Ann Rheum Dis; 2018 Aug; 77(8):1143-1149. PubMed ID: 29695500
[TBL] [Abstract][Full Text] [Related]
18. Sequential Therapy for Remission Induction in Severe Antineutrophil Cytoplasmic Autoantibody-Associated Glomerulonephritis.
Kant S; Habbach A; Gapud EJ; Manno RL; Gattu R; Seo P; Geetha D
Am J Nephrol; 2019; 50(5):386-391. PubMed ID: 31593967
[TBL] [Abstract][Full Text] [Related]
19. Favorable efficacy of rituximab in ANCA-associated vasculitis patients with excessive B cell differentiation.
Miyazaki Y; Nakayamada S; Kubo S; Ishikawa Y; Yoshikawa M; Sakata K; Iwata S; Miyagawa I; Nakano K; Tanaka Y
Arthritis Res Ther; 2020 Jun; 22(1):141. PubMed ID: 32539843
[TBL] [Abstract][Full Text] [Related]
20. Rituximab versus cyclophosphamide for ANCA-associated vasculitis with renal involvement.
Geetha D; Specks U; Stone JH; Merkel PA; Seo P; Spiera R; Langford CA; Hoffman GS; Kallenberg CG; St Clair EW; Fessler BJ; Ding L; Tchao NK; Ikle D; Jepson B; Brunetta P; Fervenza FC;
J Am Soc Nephrol; 2015 Apr; 26(4):976-85. PubMed ID: 25381429
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
